

Inbjudan har gått till neurologer med kopia till verksamhetschef



LUNDBECK
**SCIENCE
FORUM
NEUROLOGY**
2026 12 – 13 MARCH
COPENHAGEN, DENMARK

Welcome to a two-day face-to-face neurology symposium in Copenhagen, organized by Lundbeck.

We have an excellent program of international speakers in neurology covering different topics relevant for both clinicians and researchers in neurology. Lundbeck invites clinical neurologists to join our scientific symposium.

When Thursday 12th – Friday 13th March 2026

Where Tivoli Hotel & Congress Center
Arni Magnussons Gade 2, 1577 København

This invitation is for healthcare professionals only.



AGENDA

DAY ONE – THURSDAY 12TH MARCH

| | |
|----------------------|---|
| 11.00 - 12.30 | Arrival and Registration <i>Lunch will be available in the lobby by the auditorium</i> |
| 12.30 - 12.45 | Research & Development at Lundbeck – Transferring good basic research into innovative medicine to patients suffering from brain diseases <i>Professor Morten Grunnet, PhD, DrSc, Vice President, Head of Neuroscience Global Research, H. Lundbeck, Valby, Denmark</i> |
| 12.45 - 14.30 | SESSION 1 Neuroimmunology <i>Chair: Rolf Fronczek</i> |
| 12.45 - 13.30 | Understanding, detecting, and stimulating consciousness recovery after acute brain injury Coma is a medical and socioeconomic emergency. Although underfunded, research on coma and disorders of consciousness has made impressive progress over the last decade. To highlight these accomplishments, this lecture provides a comprehensive overview of recent advancements and future challenges related to the understanding, detection, and stimulation of consciousness recovery in the intensive care unit. <i>Daniel Kondziella, Clinical Professor of Neurology (Acute and Critical Care Neurology), Consultant Neurologist, MD, MSc, Dr philos, FEBN, Department of Neurology, Copenhagen University Hospital, Denmark</i> |
| 13.30 - 13.45 | Short break |
| 13.45 - 14.30 | Targeting Epstein-Barr Virus in Multiple Sclerosis: When and How This talk will review the mounting evidence implicating EBV in the pathogenesis of MS, and will explore current and emerging strategies for targeting EBV – including antiviral, immunotherapeutic and vaccination approaches – in the clinical management of MS. The session will highlight when such interventions may be appropriate and how they might integrate with existing disease-modifying therapies. <i>Prof. Gavin Giovannoni, MBBCh, PhD, neurologist at the Royal London Hospital and a professor at Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.</i> |
| 14.30-15.00 | BREAK with coffee, tea, and snacks |



AGENDA

DAY ONE – THURSDAY 12TH MARCH

| | |
|----------------------|--|
| 15.00 - 15.45 | SESSION 2 <i>Chairs: Rolf Fronczek & Henrik Winther Schytz</i> |
| | Poster at-a-glance presentation 5 min per presenter (depending on the number of posters) |
| 15.45 - 16.00 | Short break |
| 16.00 - 17.45 | SESSION 3 Headache disorders <i>Chair: Marja-Liisa Sumelahti</i> |
| 16.00 - 16.45 | Neurovascular mechanisms in migraine: a focus on the role of sex hormones and neuropeptides This presentation will cover translational insights into how neurovascular regulation and female sex-steroid fluctuations contribute to migraine pathophysiology and will highlight how CGRP-based therapeutics, as well as future targets, affect clinical neurological decision-making. Implications for migraine male as well as female patients across different reproductive life-stages (menstruation, pregnancy, menopause) will be emphasized. <i>Prof. Dr. Antoinette Maassen van den Brink</i> <i>Professor of Neurovascular Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands</i> |
| 16.45 - 17.00 | Short break |
| 17.00 - 17.45 | The pressure of headache – From Spontaneous Intracranial Hypotension to Idiopathic Intracranial Hypertension Spontaneous intracranial hypotension (SIH) and idiopathic intracranial hypertension (IIH) are among the most frequent secondary headache disorders, yet often underrecognized beyond their typical positional presentation. This lecture will explore their clinical spectrum, red flags, common misconceptions about cerebrospinal fluid (CSF) disorders, alongside key diagnostics and treatment approaches. <i>PD Dr. Katharina Wolf</i> <i>Privat Lecturer, Consultant Neurologist,</i> <i>Head of CSF Outpatient Clinic, Freiburg CSF Center, Department of Neurosurgery, Medical Center, University of Freiburg, Germany</i> |
| 17.45 - 18.00 | Wrap-up and summary |
| 19.30 - | Dinner at Tivoli Hotel Restaurant |



AGENDA

DAY TWO – FRIDAY 13TH MARCH

| | |
|----------------------|---|
| 09.00 - 10.45 | SESSION 4 Neurovascular disorders <i>Chair: Henrik Winther Schytz</i> |
| 09.00 - 09.45 | Carotid artery disease: current practice and future directions <p>The recently finished 2nd European Carotid Surgery Trial (ECST-2) examined whether surgery still offers advantages over optimized medical therapy for patients with carotid artery stenosis. The findings showed no clear additional benefit of surgery compared to modern medication-based treatment for patients with a low or moderate stroke risk. This result challenges long-standing treatment guidelines. Future research will focus on identifying which high-risk patients may still require surgical intervention, largely based on imaging of the vulnerable plaque. Overall, current evidence marks a shift toward more personalized treatment decisions in carotid artery disease.</p> <p><i>Dr Paul J Nederkoorn (MD, PhD), Stroke Neurologist, Clinical Epidemiologist, Department of Neurology, Amsterdam University Medical Centers (AUMC), The Netherlands</i></p> |
| 09.45 - 10.00 | Short break |
| 10.00 - 10.45 | From Imaging to Outcome in Acute Stroke <p>This presentation will explore how modern neuroimaging redefines the acute stroke paradigm – from simply treating by time to treating by tissue. We will discuss how imaging biomarkers guide reperfusion therapy and secondary prevention, predict outcomes, and pave the way for personalized stroke care.</p> <p><i>Prof. Mirjam R Heldner, MD, MSc, Deputy Head, Neurovascular Outpatient Clinics, Stroke Center, Department of Neurology, University Hospital Bern, Bern, Switzerland</i></p> |
| 10.45 - 11.00 | Short break |
| 11.00 - 12.45 | SESSION 5 Neurodegenerative disorders <i>Chair: Andreas Gantenbein</i> |
| 11.00 - 11.45 | Diagnosing Parkinsonism – from clinical criteria to biological definitions <p>Parkinson's Disease shares many clinical features with other entities within the spectrum of degenerative parkinsonian disorders. Recent revised clinical criteria for MSA have been developed to enhance diagnostic accuracy between PD and its closest clinical mimic. Nonetheless clinicopathological series have found accuracy rates of maximally 90%. Current research efforts concentrate on 'biological criteria' for disease definition and some of the markers used in these frameworks already have utility in clinical differential diagnosis between PD and atypical parkinsonism.</p> <p><i>Prof. Werner Poewe, MD, PhD, emeritus Professor of Neurology & Past Chair, Dept. of Neurology, Medical University, Innsbruck, Austria</i></p> |



AGENDA

DAY TWO – FRIDAY 13TH MARCH

| | |
|--------------------|---|
| 11.45-12.00 | Short break |
| 12.00-12.45 | Towards Early Detection: Seizure Activity as a Prodromal Symptom in FTD Epileptic seizure activity may represent a prodromal feature of frontotemporal dementia (FTD), supported by recent epidemiologic evidence showing increased rates of epilepsy and antiseizure-medication use years before FTD diagnosis. Overlapping neurophysiological and neuropathologic mechanisms between epileptogenesis and early FTD may underlie this association, highlighting potential opportunities for earlier detection and intervention. <i>Dr. Eino Solje, MD, PhD, Associate Professor & Director of the UEF Brain Research Unit, University of Eastern Finland, Kuopio, Finland, and Deputy Chief of Neurology, Kuopio University Hospital, Kuopio, Finland</i> |
| 12.45-13.00 | Closing remarks (sandwich to go) |

The symposium is open for attendance to neurology clinicians from Austria, Denmark, Belgium, Finland, Norway, Sweden, Switzerland and the Netherlands.



Registration

To register please click on the registration link below:

[Lundbeck Science Forum 2026 Registration Link](#)

Registration deadline: 22 February 2026

Information to poster presenters

If you are a clinician conducting research, especially early career researchers doing post-graduate or post-doc studies, please join our poster session! To join the poster session, you must submit an abstract to piuk@lundbeck.com deadline **1st February 2026**. After submission all abstracts will be reviewed.

Brief abstract and poster instructions

- The posters should primarily be focused on general, not product specific research, within the field of neurology. This includes, for example, preclinical, clinical research, registry-based studies and health economy.
- If research on a specific Lundbeck drug agent is included no off-label data outside indication will be allowed in the abstract or the poster.
- Lastly, the poster must reflect the content of the abstract.

Information about travel and accommodation

For attendees traveling from Denmark, Finland, Netherlands, Belgium, Switzerland, and Austria, Lundbeck can support with travel and accommodation (one night 12-13th March). Once you have registered, a travel agency will make all travel arrangements. Accommodation will be at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 Copenhagen www.tivolihotel.dk

Meals (lunch on 12th and 13th March and dinner in the evening of 12th March) will be included for symposium attendees from all countries.

If you have any questions about this meeting please contact the planning committee, we would be happy to respond to your queries.

With best regards

Pirathiv Kugathanan

Medical advisor, Lundbeck Pharma, Denmark
piuk@lundbeck.com or +45 30 83 65 52

René Nielsen

Sales, Marketing and Compliance Coordinator, Lundbeck Pharma, Denmark
rnei@lundbeck.com or +45 30 83 24 41

Utbildningen är kostnadsfri. Lundbeck står för föreläsare, lokal och måltider. Försändelsen är utsänd med stöd av uppgifter ur Hälso- och Sjukvårdens Adressregister, HSAR, av H. Lundbeck AB, som är anslutet till Integritetsskyddsprogrammet för HSAR. Ytterligare information erhålls av IQVIA Solutions Sweden AB, e-mail: adressuppdatering@iqvia.com

